For example, a combined score of TILs and tumor cellularity (CelTIL) measured at week 2 after starting neoadjuvant anti-HER2 therapy (without chemotherapy) provided predictive information in the PAMELA study56 and was recently evaluated for long-term outcome prediction in the NeoALTTO trial57. This evidence concerns the gene ERBB2 and neoplasm.